What it's for (Indications)
- Brivaracetam is an antiepileptic drug (AED) primarily indicated for the treatment of partial-onset seizures, with or without secondary generalization, in patients aged 4 years and older.
- It is approved for use as adjunctive therapy, meaning it is used in combination with other antiepileptic medications, as well as monotherapy for adults and pediatric patients aged 16 years and older.
- The efficacy and safety of brivaracetam have been established through well-controlled clinical trials demonstrating its ability to reduce seizure frequency in the target patient population.
- Healthcare providers consider brivaracetam for patients who require effective seizure control and tolerate its adverse effect profile, often integrating it into existing treatment regimens or initiating it as a primary therapeutic option based on individual patient needs and seizure characteristics.
- Its utility extends to a broad age range, providing a valuable option for managing a common form of epilepsy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Brivaracetam is available in oral formulations (tablets, oral solution) and an intravenous (IV) solution. For adults and pediatric patients 16 years and older, the recommended initial dose is 50 mg twice daily (100 mg/day). Depending on individual patient response and tolerability, the dose may be adjusted between 25 mg twice daily (50 mg/day) and 100 mg twice daily (200 mg/day). For pediatric patients aged 4 to less than 16 years, dosing is weight-based, starting typically at 0.5-1 mg/kg twice daily, with a maximum recommended dose of 2 mg/kg twice daily, not exceeding 100 mg twice daily. Dose adjustments are necessary for patients with hepatic impairment, typically reducing the maximum daily dose by half. No dose adjustments are generally required for patients with renal impairment, though caution is advised in severe cases. The IV formulation can be used when oral administration is temporarily not feasible, with the same dose and frequency as the oral formulation. Administration should occur gradually upon discontinuation of therapy to minimize the risk of increased seizure frequency. |
Safety & Warnings
Common Side Effects
- Brivaracetam is associated with a range of side effects, with some of the most common including somnolence (drowsiness), dizziness, fatigue, nausea, and vomiting.
- Patients may also experience psychiatric symptoms such as irritability, aggression, depression, anxiety, and insomnia.
- Less common but serious adverse reactions include psychiatric and behavioral disturbances like psychotic symptoms, suicidal ideation and behavior, and mood changes, which necessitate close monitoring.
- Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported and require immediate medical attention.
- Other potential side effects involve central nervous system effects such as coordination problems and balance disturbances.
- Hematologic abnormalities, including decreased white blood cell counts, have been observed in clinical trials, warranting consideration in patients with pre-existing conditions or those on concomitant medications that may affect blood counts.
- Patients should be counseled on these potential effects and advised to report any concerning symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: Brivaracetam does not carry a specific FDA Black Box Warning. However, like all antiepileptic drugs (AEDs), it carries a significant warning regarding an increased risk of suicidal thoughts or behavior (suicidality) in patients taking these medications for any indication. This risk was observed in a meta-analysis of randomized, placebo-controlled clinical trials of AEDs. Patients, their caregivers, and families should be advised of the need to monitor for the emergence or worsening of depression, unusual changes in mood or behavior, or suicidal thoughts, behavior, or self-harm. Such symptoms should be reported immediately to a healthcare provider. While the precise mechanism of this risk is not fully understood, it necessitates careful patient monitoring and prompt intervention. Furthermore, abrupt discontinuation of brivaracetam can lead to increased seizure frequency or status epilepticus, highlighting the critical importance of gradual withdrawal under medical supervision. Hypersensitivity reactions, including angioedema and anaphylaxis, have also been reported, requiring immediate medical attention and discontinuation of the drug.
- Several significant warnings are associated with brivaracetam use.
- Patients should be closely monitored for psychiatric adverse reactions, including behavioral changes, aggression, depression, anxiety, and psychotic symptoms, which can occur at any time during treatment.
- There is an increased risk of suicidal thoughts or behavior (suicidality) in patients taking antiepileptic drugs (AEDs) like brivaracetam; therefore, patients, caregivers, and families must be vigilant for changes in mood, behavior, or the emergence of suicidal ideation.
- Brivaracetam can cause central nervous system (CNS) depression, leading to somnolence and dizziness, which may impair a patient's ability to drive or operate machinery, especially during initial dose titration.
- Hypersensitivity reactions, such as angioedema and anaphylaxis, are possible and require immediate discontinuation and appropriate medical management.
- Abrupt withdrawal of brivaracetam should be avoided as it can precipitate an increase in seizure frequency or status epilepticus; doses should be tapered gradually under medical supervision.
- Patients with hepatic impairment require dose adjustments due to reduced clearance of the drug.
How it Works (Mechanism of Action)
Brivaracetam exerts its antiepileptic effects primarily through high and selective affinity for synaptic vesicle glycoprotein 2A (SV2A) in the brain. SV2A is a ubiquitous transmembrane protein found in synaptic vesicles, and its exact physiological role in neurotransmission is still being elucidated. However, binding to SV2A is believed to modulate synaptic vesicle release, thereby stabilizing hyperexcitable neuronal membranes and reducing synchronized neuronal firing that characterizes epileptic seizures. Unlike some other antiepileptic drugs, brivaracetam does not appear to significantly interact with voltage-gated sodium channels, GABA receptors, or other common antiepileptic targets at clinically relevant concentrations. This highly selective binding to SV2A distinguishes brivaracetam and contributes to its efficacy in managing partial-onset seizures. The precise downstream effects of SV2A modulation by brivaracetam are complex but ultimately lead to a reduction in seizure activity by dampening neuronal overactivity.
Commercial Brands (Alternatives)
No other brands found for this formula.